Chugai Pharmaceutical Co.... (CHGCY)
Chugai Pharmaceutical Statistics
Share Statistics
Chugai Pharmaceutical has 3.29B shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 3.29B |
| Shares Change (YoY) | 0.01% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 639.66M |
| Failed to Deliver (FTD) Shares | 1.03K |
| FTD / Avg. Volume | 0.48% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 29.37 and the forward PE ratio is null. Chugai Pharmaceutical's PEG ratio is 1.55.
| PE Ratio | 29.37 |
| Forward PE | n/a |
| PS Ratio | 9.72 |
| Forward PS | null |
| PB Ratio | 5.98 |
| P/FCF Ratio | 28.97 |
| PEG Ratio | 1.55 |
Enterprise Valuation
Chugai Pharmaceutical has an Enterprise Value (EV) of 5,147.7B.
| EV / Sales | 4.4 |
| EV / EBITDA | 9.5 |
| EV / EBIT | 11.5 |
| EV / FCF | 13.11 |
Financial Position
The company has a current ratio of 5.53, with a Debt / Equity ratio of 0.
| Current Ratio | 5.53 |
| Quick Ratio | 4.7 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -527.75 |
Financial Efficiency
Return on Equity is 20.37% and Return on Invested Capital is 20.16%.
| Return on Equity | 20.37% |
| Return on Assets | 17.54% |
| Return on Invested Capital | 20.16% |
| Revenue Per Employee | $232.91M |
| Profits Per Employee | $77.06M |
| Employee Count | 5,026 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | 155.72B |
| Effective Tax Rate | 28.68% |
Stock Price Statistics
The stock price has increased by 78.31% in the last 52 weeks. The beta is 0.7, so Chugai Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 78.31% |
| 50-Day Moving Average | 23.75 |
| 200-Day Moving Average | 22.65 |
| Relative Strength Index (RSI) | 79.38 |
| Average Volume (20 Days) | 215.91K |
Income Statement
In the last 12 months, Chugai Pharmaceutical had revenue of 1,170.6B and earned 387.32B in profits. Earnings per share was 235.35.
| Revenue | 1,170.6B |
| Gross Profit | 831.2B |
| Operating Income | 542B |
| Net Income | 387.32B |
| EBITDA | 542B |
| EBIT | 542B |
| Earnings Per Share (EPS) | 235.35 |
Balance Sheet
The company has 540.2B in cash and 0 in debt, giving a net cash position of 540.2B.
| Cash & Cash Equivalents | 540.2B |
| Total Debt | 0 |
| Net Cash | 540.2B |
| Retained Earnings | 0 |
| Total Assets | 2,060.2B |
| Working Capital | 1,185.9B |
Cash Flow
In the last 12 months, operating cash flow was 447.6B and capital expenditures -54.9B, giving a free cash flow of 392.7B.
| Operating Cash Flow | 447.6B |
| Capital Expenditures | -54.9B |
| Free Cash Flow | 392.7B |
| FCF Per Share | 238.62 |
Margins
Gross margin is 71.01%, with operating and profit margins of 46.3% and 33.09%.
| Gross Margin | 71.01% |
| Operating Margin | 46.3% |
| Pretax Margin | 46.39% |
| Profit Margin | 33.09% |
| EBITDA Margin | 46.3% |
| EBIT Margin | 46.3% |
| FCF Margin | 33.55% |
Dividends & Yields
CHGCY pays an annual dividend of $0.41, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | $0.41 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | 2.91% |
| Payout Ratio | 51.33% |
| Earnings Yield | 3.4% |
| FCF Yield | 6.9% |
Analyst Forecast
Currently there are no analyst rating for CHGCY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 6, 2020. It was a forward split with a ratio of 12:1.
| Last Split Date | Jul 6, 2020 |
| Split Type | forward |
| Split Ratio | 12:1 |
Scores
| Altman Z-Score | 3.27 |
| Piotroski F-Score | 5 |